Cancer Genetics offers oncomine comprehensive assay to drive clinical trials
Cancer Genetics announced the successful CLIA validation and commercial launch of Thermo Fisher Scientific’s next-generation sequencing Oncomine Comprehensive Assay v3 for biopharma clinical trials. Oncomine Comprehensive Assay v3 features content based on the advances in clinical oncology research. September 20, 2018